Display options
Cite
He JJ, Zhang WH, Liu SL, et al. Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma. Oncol Lett. 2017;14(3):3846-3852doi: 10.3892/ol.2017.6653.
He, J. J., Zhang, W. H., Liu, S. L., Chen, Y. F., Liao, C. X., Shen, Q. Q., & Hu, P. (2017). Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma. Oncology letters, 14(3), 3846-3852. https://doi.org/10.3892/ol.2017.6653
He, Jing-Jing, et al. "Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma." Oncology letters vol. 14,3 (2017): 3846-3852. doi: https://doi.org/10.3892/ol.2017.6653
He JJ, Zhang WH, Liu SL, Chen YF, Liao CX, Shen QQ, Hu P. Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma. Oncol Lett. 2017 Sep;14(3):3846-3852. doi: 10.3892/ol.2017.6653. Epub 2017 Jul 21. PMID: 28927156; PMCID: PMC5587982.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Sep;14(3):3846-3852. doi: 10.3892/ol.2017.6653. Epub 2017 Jul 21.

Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma.

Oncology letters

Jing-Jing He, Wen-Hua Zhang, Shi-Ling Liu, Yi-Fang Chen, Chen-Xi Liao, Qian-Qing Shen, Ping Hu

Affiliations

  1. Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330001, P.R. China.
  2. Institute of Life Science, Nanchang University, Nanchang, Jiangxi 330031, P.R. China.

PMID: 28927156 PMCID: PMC5587982 DOI: 10.3892/ol.2017.6653

Abstract

Glioblastoma multiforme is the most common and aggressive form of primary malignant brain tumor. Previous evidence demonstrates that β-adrenergic receptors (β-ARs) are closely associated with the occurrence and development of brain tumors. However, the functional role of β-ARs in human glioblastoma and the underlying mechanisms are not fully understood. In the present study, by using the MTT assay, western blotting, and the reverse transcription polymerase chain reaction, it was revealed that isoproterenol (ISO), an agonist of β-ARs, promoted the proliferation of U251 cells but not U87-MG cells, and that this effect was blocked by the β-ARs antagonist propranolol. It was also demonstrated that ISO transiently induced extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation, and that blocking the mitogen-activated protein kinase pathway by U0126 inhibited ERK1/2 phosphorylation and suppressed U251 cell proliferation. In addition, β-ARs activation increased the expression of matrix metalloproteinase (MMP) family members

Keywords: glioblastoma; isoproterenol; mitogen-activated protein kinase; proliferation; β-adrenergic receptor

References

  1. J Pharmacol Exp Ther. 2011 Feb;336(2):524-32 - PubMed
  2. Biochemistry. 2007 May 1;46(17 ):5106-13 - PubMed
  3. Oncol Rep. 2011 Dec;26(6):1471-7 - PubMed
  4. Oncol Lett. 2013 Jan;5(1):221-225 - PubMed
  5. Int J Oncol. 2012 May;40(5):1714-24 - PubMed
  6. Acta Biochim Biophys Sin (Shanghai). 2011 Nov;43(11):840-8 - PubMed
  7. Cancer Metastasis Rev. 2006 Mar;25(1):9-34 - PubMed
  8. Toxicol Sci. 2007 Mar;96(1):21-9 - PubMed
  9. Future Oncol. 2010 Dec;6(12):1863-81 - PubMed
  10. Methods. 2001 Dec;25(4):402-8 - PubMed
  11. Carcinogenesis. 2001 Mar;22(3):473-9 - PubMed
  12. Cancer. 2008 Feb 15;112(4):767-78 - PubMed
  13. JAMA. 2007 Oct 10;298(14):1685-7 - PubMed
  14. Pancreas. 2012 Nov;41(8):1306-15 - PubMed
  15. Front Oncol. 2015 Jan 12;4:375 - PubMed
  16. Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49 - PubMed
  17. N Engl J Med. 2008 Jul 31;359(5):492-507 - PubMed
  18. Mol Cell Biol. 2001 Dec;21(24):8452-60 - PubMed
  19. Oncogene. 2007 May 14;26(22):3279-90 - PubMed
  20. Oncol Rep. 2010 Jan;23(1):151-7 - PubMed
  21. Ann Oncol. 2009 May;20 Suppl 4:126-8 - PubMed
  22. Oncol Rep. 2015 May;33(5):2513-20 - PubMed
  23. Neuroscience. 2013 Sep 17;248:626-36 - PubMed
  24. Oncotarget. 2010 Nov;1(7):466-9 - PubMed
  25. Future Oncol. 2010 Feb;6(2):221-8 - PubMed
  26. Nat Rev Cancer. 2002 Mar;2(3):161-74 - PubMed
  27. Int J Cancer. 2009 Jan 15;124(2):257-63 - PubMed
  28. Breast Cancer Res Treat. 2000 Mar;60(2):153-66 - PubMed
  29. Anticancer Drugs. 2009 Jul;20(6):477-82 - PubMed
  30. J Clin Invest. 2013 Feb;123(2):874-86 - PubMed
  31. J Clin Invest. 2013 Feb;123(2):558-60 - PubMed
  32. Br J Pharmacol. 2010 Mar;159(5):1022-38 - PubMed
  33. J Cell Biochem. 1985;29(2):127-41 - PubMed
  34. Nat Rev Neurosci. 2005 Jun;6(6):463-75 - PubMed
  35. Oncol Rep. 2016 Sep;36(3):1757-63 - PubMed
  36. J Biol Chem. 2013 Oct 4;288(40):29193-205 - PubMed
  37. Acta Pharmacol Sin. 2012 Mar;33(3):335-41 - PubMed
  38. Pharmacol Res. 2009 Nov;60(5):438-45 - PubMed
  39. Oncogene. 2007 May 31;26(26):3777-88 - PubMed
  40. Nat Med. 2006 Aug;12 (8):939-44 - PubMed
  41. Cell Signal. 2012 Jan;24(1):333-41 - PubMed
  42. J Cancer Res Clin Oncol. 2005 Oct;131(10 ):639-48 - PubMed
  43. J Pharmacol Exp Ther. 2012 Oct;343(1):157-66 - PubMed

Publication Types